IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, Y.
Right arrow Articles by Leppla, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, Y.
Right arrow Articles by Leppla, S. H.

 Previous Article  |  Next Article 

Infect Immun, July 1998, p. 3447-3448, Vol. 66, No. 7
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Study of Immunization against Anthrax with the Purified Recombinant Protective Antigen of Bacillus anthracis

Yogendra Singh,1,* Bruce E. Ivins,2 and Stephen H. Leppla3

Centre for Biochemical Technology, Delhi, India,1 and Bacteriology Division, U.S. Army Medical Research Institute for Infectious Diseases, Fort Detrick, Frederick,2 and Oral Infection and Immunity Branch, National Institute of Dental Research, National Institutes of Health, Bethesda,3 Maryland

Received 30 January 1998/Returned for modification 6 March 1998/Accepted 16 April 1998

Protective antigen (PA) of anthrax toxin is the major component of human anthrax vaccine. Currently available human vaccines in the United States and Europe consist of alum-precipitated supernatant material from cultures of toxigenic, nonencapsulated strains of Bacillus anthracis. Immunization with these vaccines requires several boosters and occasionally causes local pain and edema. We previously described the biological activity of a nontoxic mutant of PA expressed in Bacillus subtilis. In the present study, we evaluated the efficacy of the purified mutant PA protein alone or in combination with the lethal factor and edema factor components of anthrax toxin to protect against anthrax. Both mutant and native PA preparations elicited high anti-PA titers in Hartley guinea pigs. Mutant PA alone and in combination with lethal factor and edema factor completely protected the guinea pigs from B. anthracis spore challenge. The results suggest that the mutant PA protein may be used to develop an effective recombinant vaccine against anthrax.

* Corresponding author. Mailing address: Centre for Biochemical Technology, Mall Road, Near Jubilee Hall, Delhi 110 007, India. Phone: (91) 11-7256157. Fax: (91) 11-725 7471. E-mail: cbt{at}delnet.ren.nec.in.

Infect Immun, July 1998, p. 3447-3448, Vol. 66, No. 7
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 1998 by the American Society for Microbiology. All rights reserved.